Articles Referencing CRL
Good News for Novartis' Ilaris - Analyst Blog
5/15/2013, 6:29 pm from Zacks.com in Investing, Business, Stocks
Novartis ( NVS ) recently
announced that the US Food and Drug Administration (FDA) has
approved Ilaris (canakinumab) for an additional indication.
Ilaris is now approved for the... Read >>
Salix Beats on Earnings - Analyst Blog
5/14/2013, 10:28 am from Zacks.com in Investing, Business, Earnings, Stocks
Salix Pharmaceuticals, Ltd. ( SLXP ) posted first
quarter earnings of 56 cents per share, above the Zacks Consensus
Estimate of 55 cents and the year-ago earnings of 42 cents.
Excluding... Read >>
ABCO Posts Solid 4Q and FY2013 Earnings - Analyst Blog
5/13/2013, 10:50 am from Zacks.com in Investing, Business, Earnings, Stocks
The Advisory Board Company ( ABCO ) reported fourth
quarter fiscal 2013 operating earnings of 33 cents per share
surpassing the Zacks Consensus Estimate of 21 cents per share.
Results also... Read >>
Charles River Misses Estimates in 1Q - Analyst Blog
5/2/2013, 1:44 pm from Zacks.com in Investing, Business, Stocks
Charles River Laboratories ( CRL ) reported first
quarter 2013 earnings (excluding special items) of 63 cents per
share, missing the Zacks Consensus Estimate of 71 cents. Earnings
were... Read >>
Glaxo-Impax End Rytary Deal - Analyst Blog
4/30/2013, 4:48 pm from Zacks.com in Investing, Business, Stocks
GlaxoSmithKline ( GSK ) and Impax
Pharmaceuticals, the brand products division of Impax
Laboratories, Inc. ( IPXL ), recently
announced the termination of their agreement for Rytary... Read >>
Data on Teva's Milprosa - Analyst Blog
4/18/2013, 7:13 pm from Zacks.com in Investing, Business, Stocks
Teva Pharmaceuticals ( TEVA ) recently
announced new data from a phase III study on Milprosa
(progesterone) vaginal ring which is being developed for luteal
phase support in women... Read >>
Priority Review for Bayer's Riociguat - Analyst Blog
4/9/2013, 4:08 pm from Zacks.com in Investing, Business, Stocks
Bayer 's ( BAYRY ) HealthCare
segment recently received encouraging news from the US Food and
Drug Administration (FDA) as it granted priority review designation
to the New Drug Application... Read >>
Data Presented on Bayer's ATX-101 - Analyst Blog
4/8/2013, 6:10 pm from Zacks.com in Investing, Business, Stocks
Bayer AG ( BAYRY ) recently
presented positive results on ATX-101 at the 11th Anti-Aging
Medicine World Congress (AMWC) 2013. ATX-101 is being developed for
the reduction of unwanted fat... Read >>
Glaxo's Flu Vaccine Approved - Analyst Blog
4/8/2013, 5:00 pm from Zacks.com in Investing, Business, Stocks
GlaxoSmithKline ( GSK ) recently
announced the receipt of marketing authorization for its
four-strain seasonal influenza vaccine in Germany and the UK. The
vaccine will be marketed as... Read >>
Glaxo's Influenza Vaccine Gets CRL - Analyst Blog
4/1/2013, 6:50 pm from Zacks.com in Investing, Business, Stocks
GlaxoSmithKline ( GSK ) recently received
a complete response letter (CRL) from the US Food and Drug
Administration (FDA) regarding the company's influenza vaccine
candidate, Q-Pan H5N1... Read >>
Japanese Approval for Bayer's drug - Analyst Blog
3/27/2013, 2:25 pm from Zacks.com in Investing, Business, Stocks
Bayer 's ( BAYRY ) HealthCare
segment recently received encouraging news as the Ministry of
Health, Labour and Welfare (MHLW) in Japan approved Stivarga
(regorafenib). Stivarga is approved... Read >>
Another CRL for UTHR's Oral Remodulin - Analyst Blog
3/26/2013, 4:26 pm from Zacks.com in Investing, Business, Stocks
The US Food and Drug Administration (FDA) recently issued a
second complete response letter (CRL) for United
Therapeutics Corporation's ( UTHR ) new drug
application for oral Remodulin... Read >>
CHMP Positive on Bayer's Xarelto - Analyst Blog
3/25/2013, 5:28 pm from Zacks.com in Investing, Business, Stocks
Bayer 's ( BAYRY ) HealthCare
segment recently received a positive recommendation from the
European Committee for Medicinal Products for Human Use (CHMP) for
Xarelto (rivaroxaban) in... Read >>
Good News for Novartis Candidate - Analyst Blog
3/19/2013, 3:46 pm from Zacks.com in Investing, Business, Stocks
Novartis ( NVS ) recently
announced that the US Food and Drug Administration (FDA) rendered
Breakthrough Therapy designation to its pipeline candidate
LDK378. The Breakthrough Therapy... Read >>
Loss at OREX Narrower than Expected - Analyst Blog
3/14/2013, 5:45 pm from Zacks.com in Investing, Business, Stocks
Orexigen Therapeutics, Inc. ( OREX ) reported a net
loss of 41 cents per share in the fourth quarter of 2012, much
wider than the year-ago loss of 9 cents but 4 cents narrower than
the... Read >>